{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:10:50Z","timestamp":1778490650447,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["RC2 DK127989-01A1"],"award-info":[{"award-number":["RC2 DK127989-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA289886-01"],"award-info":[{"award-number":["1R01CA289886-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32HL125195"],"award-info":[{"award-number":["T32HL125195"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA009351"],"award-info":[{"award-number":["T32CA009351"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jtct.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:43:51Z","timestamp":1764981831000},"page":"474.e1-474.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-9164","authenticated-orcid":false,"given":"Emily C.","family":"Merkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ted","family":"Gooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica S.","family":"Thakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott N.","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Summers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle C.","family":"Kirkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Hadland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauri M.","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Goshorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Bleakley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Tarlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jtct.2025.12.003_bib0001","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00277-022-04965-x","article-title":"Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis","volume":"101","author":"Masetti","year":"2022","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.003_bib0002","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41409-021-01261-6","article-title":"Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation","volume":"56","author":"Percival","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1016\/j.jtct.2025.12.003_bib0003","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1182\/blood-2016-01-695551","article-title":"Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study","volume":"127","author":"De Rooij","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.003_bib0004","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children\u2019s Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.003_bib0005","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41409-019-0461-0","article-title":"Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia","volume":"54","author":"Okamoto","year":"2019","journal-title":"Bone Marrow Transplant 2019 549"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.003_bib0006","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/bjh.14720","article-title":"Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia","volume":"178","author":"Karlsson","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.003_bib0007","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.bbmt.2018.06.010","article-title":"Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and wilms tumor 1 gene expression","volume":"24","author":"Jacobsohn","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.003_bib0008","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2025.12.003_bib0009","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.003_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102336","article-title":"Survival following relapse in children with acute myeloid leukemia: a report from AML-BFM and COG","volume":"13","author":"Rasche","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.003_bib0011","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41409-019-0438-z","article-title":"Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children","volume":"54","author":"Dahlberg","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.003_bib0012","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2025.12.003_bib0013","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.003_bib0014","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"10.1016\/j.jtct.2025.12.003_bib0015","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.003_bib0016","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial","volume":"22","author":"Craddock","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.003_bib0017","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"De Lima","year":"2010","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.jtct.2025.12.003_bib0018","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.hemonc.2021.03.001","article-title":"Azacitidine maintenance therapy post-allogeneic stem cell transplantation in poor-risk acute myeloid leukemia","volume":"16","author":"Keruakous","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"36","key":"10.1016\/j.jtct.2025.12.003_bib0020","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.003_bib0021","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/cas.15048","article-title":"Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"112","author":"Wei","year":"2021","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.003_bib0022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.003_bib0023","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.clml.2024.01.012","article-title":"Azacitidine post-transplant maintenance improves disease progression in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Pasvolsky","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.003_bib0024","first-page":"1","article-title":"Maintenance therapy with Azacitidine for patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Lu","year":"2025","journal-title":"Sci Reports 2025 151"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.003_bib0025","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1016\/j.jtct.2025.01.659","article-title":"Oral Azacitidine use after stem cell transplantation for myeloid malignancies: a single center experience","volume":"31","author":"Sanchez-Petitto","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.12.003_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.801632","article-title":"Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis","volume":"9","author":"Kungwankiattichai","year":"2022","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.003_bib0027","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/j.bbmt.2017.12.383","article-title":"Post-transplant low-dose azacitidine can improve overall survival in aml\/mds patients and is associated with decrease risks of severe acute and chronic GVHD","volume":"24","author":"Mori","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.003_bib0028","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.003_bib0029","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.4049\/jimmunol.1502399","article-title":"Azacitidine mitigates graft-versus-host disease via differential effects on the proliferation of T effectors and natural regulatory T cells in vivo","volume":"198","author":"Cooper","year":"2017","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1314425","article-title":"Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects","volume":"6","author":"Ehx","year":"2017","journal-title":"Oncoimmunology"},{"issue":"22","key":"10.1016\/j.jtct.2025.12.003_bib0031","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1182\/blood.V128.22.4805.4805","article-title":"Azacitidine administration following hematopoietic stem cell transplantation is safe and feasible in children with acute leukemia","volume":"128","author":"Wahlstrom","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.003_bib0032","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.bbmt.2019.12.630","article-title":"Azacitidine as a post-stem cell transplant maintenance for children with acute myeloid leukemia","volume":"26","author":"Onishi","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27284","article-title":"Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia","volume":"65","author":"Tamura","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.003_bib0034","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/08880018.2020.1829220","article-title":"Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia","volume":"38","author":"Huschart","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.02.009","article-title":"Efficacy of azacitidine and prophylactic donor lymphocyte infusion after hsct in pediatric patients with acute myelogenous leukemia: a retrospective pre-post study","volume":"29","author":"Booth","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.003_bib0036","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13423","article-title":"Low-dose azacitidine for relapse prevention after allogeneic hematopoietic cell transplantation in children with myeloid malignancies","volume":"23","author":"Oshrine","year":"2019","journal-title":"Pediatr Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.003_bib0038","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"282","key":"10.1016\/j.jtct.2025.12.003_bib0039","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.003_bib0040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","article-title":"Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Zhang","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.12.003_bib0041","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/0008-5472.CAN-05-3020","article-title":"De novo induction of a cancer\/testis antigen by 5-Aza-2\u2032-deoxycytidine augments adoptive immunotherapy in a Murine Tumor Model","volume":"66","author":"Guo","year":"2006","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jtct.2025.12.003_bib0042","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2025.12.003_bib0043","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.003_bib0044","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1\u2013targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.003_bib0045","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2025.12.003_bib0046","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.287177","article-title":"Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome","author":"Smallbone","year":"2025","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.003_bib0047","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase ii study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.003_bib0048","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"58","author":"Kent","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.003_bib0049","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.003_bib0050","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2343604","article-title":"Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis","volume":"29","author":"He","year":"2024","journal-title":"Hematology"},{"issue":"3","key":"10.1016\/j.jtct.2025.12.003_bib0051","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/jha2.915","article-title":"Low-dose decitabine plus venetoclax as post-transplant maintenance for high-risk myeloid malignancies","volume":"5","author":"Parks","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.jtct.2025.12.003_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.810387","article-title":"Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia","volume":"11","author":"Ciotti","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.003_bib0053","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s44228-022-00019-1","article-title":"Azacitidine in combination with venetoclax maintenance post-allogeneic hematopoietic stem cell transplantation in T cell acute lymphoblastic leukemia","volume":"5","author":"Hassan","year":"2023","journal-title":"Clin Hematol Int"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.003_bib0054","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbmt.2018.03.002","article-title":"Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study","volume":"24","author":"Yaniv","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"0","key":"10.1016\/j.jtct.2025.12.003_bib0055","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy \u2013 a report from the CIBMTR","volume":"0","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.003_bib0056","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.12.003_bib0057","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2023-189080","article-title":"Pre-transplant levels of multiparametric flow-cytometry measurable residual disease (MFC-MRD) predict outcomes in children with acute myeloid leukemia given allogeneic hematopoietic stem cell transplantation","volume":"142","author":"Buldini","year":"2023","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725016379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725016379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:37:22Z","timestamp":1778488642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725016379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666636725016379"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}